| Trial ID: | L2282 |
| Source ID: | NCT05751720
|
| Associated Drug: |
Gip/Glp-1a
|
| Title: |
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis|Type 2 Diabetes|Liver Fat
|
| Interventions: |
DRUG: GIP/GLP-1a
|
| Outcome Measures: |
Primary: change in liver stiffness in terms of kPa, To measure the liver stiffness pre and post GLP-1 analogue/GIP treatment for 6 months to assess any change in liver stiffness in terms of kPa in patient with type 2 Diabetes Mellitus and NAFLD, 12 months|Change in Liver fat quantification, To measure the liver fat quantification via MRI proton density fraction, pre and post GLP-1 analogue/GIP treatment for 6 months to assess any change in total liver fat content in patients with type 2 Diabetes Mellitus and NAFLD, 12 months | Secondary: change in BMI, To measure the body mass index (weight in Kg and height in metres will be combined to report BMI in kg/m2), pre and post GLP-1 analogue/GIP treatment for 6 months to assess any change in BMI in patients with type 2 Diabetes Mellitus and NAFLD, 12 months|Glycaemic control, To measure the HbA1c, pre and post GLP-1 analogue/GIP treatment for 6 months to assess any change in HbA1c in patients with type 2 Diabetes Mellitus and NAFLD, 12 months
|
| Sponsor/Collaborators: |
Sponsor: Dr Adnan Agha
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-10-01
|
| Completion Date: |
2025-02
|
| Results First Posted: |
|
| Last Update Posted: |
2024-01-12
|
| Locations: |
Internal Medicine, College of Medicine and Health Sciences, Al Ain, Abu Dhabi, 15551, United Arab Emirates
|
| URL: |
https://clinicaltrials.gov/show/NCT05751720
|
